Microbiome Therapeutics US is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Mark Smith
CEO at Finch Therapeutics

Profile

Through his work at Finch, Mark Smith is unlocking the potential of the microbiome to improve human health. With a background in computational microbiology, he is deeply interested in the complex interactions between humans and our hidden microbial majority and the development of new therapies that use these interactions to address important unmet medical needs.

Agenda Sessions

  • VCs vs Pharma: changing landscape of funding models

    ,
  • Microbiome 101 for investors

    ,